Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday. Separately, JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” […]
Related Keywords
,News Ratings For Enanta Pharmaceuticals Daily ,Acadian Asset Management ,Enanta Pharmaceuticals Inc ,Enanta Pharmaceuticals ,Jpmorgan Chase Co ,Enanta Pharmaceuticals Price Performance ,Krensavage Asset Management ,Hedge Funds Weigh In On Enanta Pharmaceuticals ,Analyst Recommendations For Enanta Pharmaceuticals ,Get Free Report ,Asset Management ,State Street Corp ,Street Corp ,Enanta Pharmaceuticals Daily ,Nasdaq Enta ,Enta ,Medical ,Downgrade ,Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.